Humedix Co., Ltd. (200670.KQ)
KRW 42800.0
(3.38%)
KRW 42800.0
(3.38%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 28.62 Billion KRW | 35.45% |
| 2022 | 21.13 Billion KRW | 28.2% |
| 2021 | 16.48 Billion KRW | -13.45% |
| 2020 | 19.04 Billion KRW | 87.02% |
| 2019 | 10.18 Billion KRW | 18.92% |
| 2018 | 8.56 Billion KRW | -4.84% |
| 2017 | 9 Billion KRW | 142.23% |
| 2016 | 3.71 Billion KRW | 22.67% |
| 2015 | 3.02 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 28.02 Billion KRW | -2.08% |
| 2024 Q2 | 29.9 Billion KRW | 6.71% |
| 2023 Q3 | 27.94 Billion KRW | -2.38% |
| 2023 FY | 28.62 Billion KRW | 35.45% |
| 2023 Q2 | 28.62 Billion KRW | 8.61% |
| 2023 Q4 | 28.62 Billion KRW | 2.44% |
| 2023 Q1 | 26.35 Billion KRW | 24.71% |
| 2022 FY | 21.13 Billion KRW | 28.2% |
| 2022 Q4 | 21.13 Billion KRW | 19.93% |
| 2022 Q3 | 17.62 Billion KRW | 4.14% |
| 2022 Q2 | 16.92 Billion KRW | 5.04% |
| 2022 Q1 | 16.1 Billion KRW | -2.28% |
| 2021 FY | 16.48 Billion KRW | -13.45% |
| 2021 Q3 | 18.54 Billion KRW | -5.22% |
| 2021 Q4 | 16.48 Billion KRW | -11.09% |
| 2021 Q2 | 19.56 Billion KRW | 93451.74% |
| 2021 Q1 | 20.9 Million KRW | 9.77% |
| 2020 Q3 | 17.23 Million KRW | 16.84% |
| 2020 FY | 19.04 Billion KRW | 87.02% |
| 2020 Q4 | 19.04 Million KRW | 10.52% |
| 2020 Q1 | 12.59 Million KRW | 23.65% |
| 2020 Q2 | 14.74 Million KRW | 17.12% |
| 2019 Q4 | 10.18 Million KRW | 5.47% |
| 2019 FY | 10.18 Billion KRW | 18.92% |
| 2019 Q3 | 9.65 Million KRW | -11.03% |
| 2019 Q2 | 10.85 Million KRW | 14.73% |
| 2019 Q1 | 9.45 Million KRW | 10.45% |
| 2018 Q3 | 8.05 Million KRW | 1.31% |
| 2018 FY | 8.56 Billion KRW | -4.84% |
| 2018 Q1 | 9.35 Million KRW | 3.9% |
| 2018 Q4 | 8.56 Million KRW | 6.32% |
| 2018 Q2 | 7.95 Million KRW | -14.98% |
| 2017 FY | 9 Billion KRW | 142.23% |
| 2017 Q4 | 9 Million KRW | 7.38% |
| 2017 Q1 | 4.59 Million KRW | 23.66% |
| 2017 Q2 | 6.54 Million KRW | 42.54% |
| 2017 Q3 | 8.38 Million KRW | 27.98% |
| 2016 Q4 | 3.71 Million KRW | 0.0% |
| 2016 FY | 3.71 Billion KRW | 22.67% |
| 2016 Q1 | - KRW | 0.0% |
| 2015 FY | 3.02 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 20.85 Billion KRW | -37.238% |
| CMG Pharmaceutical Co., Ltd. | 15.87 Billion KRW | -80.308% |
| Celltrion Pharm, Inc. | 100.42 Billion KRW | 71.495% |
| Huons Global Co., Ltd. | 121.81 Billion KRW | 76.502% |
| DongKook Pharmaceutical Co., Ltd. | 138.34 Billion KRW | 79.308% |
| Enzychem Lifesciences Corporation | 14.94 Billion KRW | -91.527% |
| Boditech Med Inc. | 31.6 Billion KRW | 9.422% |
| EuBiologics Co., Ltd. | 13.34 Billion KRW | -114.558% |
| FutureChem Co.,Ltd | 1.37 Billion KRW | -1982.592% |
| Huons Co., Ltd. | 76.59 Billion KRW | 62.629% |
| BNC Korea Co., Ltd. | 11.39 Billion KRW | -151.243% |
| AptaBio Therapeutics Inc. | - KRW | -Infinity% |